MET and pancreatic neoplasm: Two (MET, PDGFRA) out of the three targets (MET, PDGFRA and PYK2) were experimentally validated as sensitizing targets of AKI-1 in the pancreatic cancer, representing a highly significant enrichment (hypergeometric test, p = 0.0046) (Figure S4 in [55]).